Treatment with Ultomiris (ravulizumab-cwvz) eased symptoms of generalized myasthenia gravis (gMG) for more than a year, according to new…
Articles by Marisa Wexler, MS
Many people with myasthenia gravis (MG) caused by antibodies against MuSK initially present with eye-related symptoms, which soon affect…
Soliris (eculizumab) is better than rituximab at controlling myasthenia gravis (MG) symptoms over a two-year period, according to…
Cabaletta Bio has been cleared by the U.S. Food and Drug Administration (FDA) to start first-in-human clinical testing of…
The risk of myasthenia gravis (MG) worsening during pregnancy is about 34%, a new study estimates. Notably, most…
Scientists described a new cellular model of the neuromuscular junction that could be useful for diagnosing myasthenia gravis (MG)…
By analyzing available research and conducting nearly 100 interviews with patients, an international team of researchers crafted a new tool…
Argenx is working toward the commercial launch of Vyvgart (efgartigimod) — recently approved by the U.S. Food and…
Throughout 2021, Myasthenia Gravis News has brought you coverage on the latest scientific advancements and clinical trials related to myasthenia…
Infants born to women with myasthenia gravis (MG) may develop a rare condition called transient neonatal myasthenia gravis…